10 results
8-K
EX-99.2
NVTAQ
Invitae Corp
22 Jun 20
Invitae and ArcherDX to create a global leader in comprehensive cancer genetics and precision oncology
4:55pm
from new and existing pharma partners supported by Invitae’s central lab Streamline S&M, G&A, and R&D Note:(1)Received breakthrough designation … Customers & Payers Tools & Channels Telehealth & Chatbots Pharma Partners Direct Channel R&D Platform Geographies Test Menu Salesforce Precision oncology
8-K
EX-99.1
NVTAQ
Invitae Corp
8 Nov 23
Invitae Reports Third Quarter 2023 Financial Results
4:05pm
the Company’s capital structure. The Company is exploring a number of options, including, but not limited to, raising capital, asset sales, business and R … &D refocusing efforts, capital expenditure and operating expense reductions and addressing its debt obligations.
Reaffirming Fiscal 2023 Outlook
8-K
EX-99.2
NVTAQ
Invitae Corp
1 Apr 20
Invitae Announces Proposed Public Offering of Common Stock
4:34pm
, additional headcount mostly in R&D and sales and marketing and bonuses), and lower collections, due to typical seasonality of payments.
These estimates
425
NVTAQ
Invitae Corp
22 Jun 20
Business combination disclosure
5:30pm
by Invitae’s central lab Streamline S&M, G&A, and R&D Note:(1)Received breakthrough designation; subject to FDA approval Revenue Synergies Cost Synergies … Pharma Partners Direct Channel R&D Platform Geographies Test Menu Salesforce Precision oncology & cancer care Subject to close of transaction
4,300
8-K/A
EX-99.1
NVTAQ
Invitae Corp
27 Sep 19
Financial Statements and Exhibits
4:16pm
.
Statutory rate
State tax
R & D credits
Others
Change in valuation allowance
Utilization of the net operating loss carryforwards may be subject
8-K/A
EX-99.1
3jbmm1z5lw mu0zu
28 Aug 19
Statement of Operations
4:05pm
424B5
9oc1nsnvre5
3 Apr 20
Prospectus supplement for primary offering
12:00am
424B5
z05gh
1 Apr 20
Prospectus supplement for primary offering
5:05pm
- Prev
- 1
- Next